Edesa Biotech financials
$3.56−2.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 | FY22 Sep 30 | FY21 Sep 30 | FY20 Sep 30 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | $328.8K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | $311.2K |
| Gross margin | — | — | — | — | — | 94.6% |
| Operating income | -$7.9M | -$7.0M | -$9.2M | -$18.4M | -$23.7M | -$6.4M |
| Net income | -$7.2M | -$6.2M | -$8.4M | -$17.5M | -$13.3M | -$6.4M |
| Net margin | — | — | — | — | — | −1935.3% |
| Diluted EPS | $-1.27 | $-1.93 | $-2.93 | $-8.37 | $-7.70 | $-5.18 |
| EBITDA | -$7.8M | -$6.8M | -$9.0M | -$18.3M | -$23.6M | -$6.3M |
| Operating cash flow | -$7.3M | -$4.9M | -$6.6M | -$12.3M | -$13.7M | -$5.0M |
| Free cash flow | -$7.3M | -$4.9M | -$6.6M | -$12.3M | -$13.7M | -$5.0M |
| Diluted shares | 5.7M | 3.2M | 2.9M | 2.1M | 1.7M | 1.2M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.8M | $1.0M | $5.4M | $7.1M | $7.8M | $7.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $43.7K | $47.2K | $0.00 |
| Total assets | $13.5M | $3.8M | $8.9M | $11.6M | $14.6M | $10.8M |
| Total liabilities | $1.1M | $1.8M | $1.8M | $2.2M | $1.5M | $1.7M |
| Shareholders' equity | $12.5M | $2.0M | $7.0M | $9.4M | $13.1M | $9.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology